Salivary Gland Dysfunction and Xerostomia

  • Mahvash NavazeshEmail author


  • Saliva plays an important role in oral and systemic health.

  • Dry mouth or xerostomia is a common complaint among patients of different ages in general and among geriatric and medically complex patients in particular.

  • Salivary gland disorders are caused by a variety of etiologic factors.

  • Salivary gland dysfunction may lead to irreversible intraoral hard and soft tissue changes and ultimately may reduce the quality of life.

  • Oral healthcare providers play a significant role in risk assessment, early detection, management, and prevention of salivary gland disorders. These are essential for maintaining a proper oral and systemic health in this patient population.

Suggested Readings

  1. 1.
    Jensen SB, Pedersen AML, Vissink A, et al. A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: prevalence, severity and impact on quality of life. Support Care Cancer. 2010;18(8):1039–60. doi: 10.1007/s00520-010-0827-8.CrossRefPubMedGoogle Scholar
  2. 2.
    Villa A, Wolff A, Aframian D, et al. World workshop on oral medicine VI: a systematic review of medication-induced salivary gland dysfunction: prevalence, diagnosis, and treatment. Clin Oral Invest. 2015;19:1563–80. doi: 10.1007/s00784-015-1488-2.CrossRefGoogle Scholar
  3. 3.
    Löfgren CD, Wickström C, Sonesson M, et al. A systematic review of methods to diagnose oral dryness and salivary gland function. BMC Oral Health. 2012;12:29. doi: 10.1186/1472-6831-12-29.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Luciano N, Valentini V, Calabrò A, et al. One year in review 2015: Sjögren’s syndrome. Clin Exp Rheumatol. 2015;33(2):259–71.PubMedGoogle Scholar
  5. 5.
    O’Connor R, David MA, Peter BA. Focused review of investigation, management and outcomes of salivary gland disease in specialty-specific journals. Br J Oral Maxillofac Surg. 2014;52(6):483–90. doi: 10.1016/j.bjoms.2014.03.016.CrossRefPubMedGoogle Scholar
  6. 6.
    Turner L, Mupparapu M, Akintoye SO. Review of the complications associated with treatment of oropharyngeal cancer: a guide to the dental practitioner. Quintessence Int. 1985;44(3):267–79. doi: 10.3290/j.qi.a29050.Google Scholar
  7. 7.
    Spolarich AE. Risk management strategies for reducing oral adverse drug events. J Evid Base Dent Pract. 2014;14:87–94. doi: 10.1016/j.jebdp.2014.04.009.CrossRefGoogle Scholar
  8. 8.
    Davies A, Bagg J, Laverty D, et al. Salivary gland dysfunction (‘dry mouth’) in patients with cancer: a consensus statement. Eur J Cancer Care. 2010;19(2):172–7. doi:10.1111/j.1365-2354. 2009.01081.x.CrossRefGoogle Scholar
  9. 9.
    Jensen SB, Pedersen AML, Vissink A, et al. A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: management strategies and economic impact. Support Care Cancer. 2010;18(8):1061–79. doi: 10.1007/s00520-010-0837-6.CrossRefPubMedGoogle Scholar
  10. 10.
    Kałużny J, Wierzbicka M, Nogala H, et al. Radiotherapy induced xerostomia: mechanisms, diagnostics, prevention and treatment–evidence based up to 2013. Otolaryngol Pol. 2014;68(1):1–14. doi: 10.1016/j.otpol.2013.09.002.CrossRefPubMedGoogle Scholar
  11. 11.
    Hanchanale S, Adkinson L, Daniel S, et al. Systematic literature review: xerostomia in advanced cancer patients. Support Care Cancer. 2015;23(3):881–8. doi: 10.1007/s00520-014-2477-8.CrossRefPubMedGoogle Scholar

For Further Information Visit the Following Websites

  1. 12.
  2. 13.
  3. 14.

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  1. 1.Division of Diagnostic Sciences, Herman Ostrow School of DentistryUniversity of Southern CaliforniaLos AngelesUSA

Personalised recommendations